[
    "\nThe full protocol is available as an attachment.  The following is a summary that is also found in the attached full protocol.\r\n\n\n\r\n\n\nPart 1:",
    {
        "title": "1)",
        "body": "Baseline assessments are taken the evening before dosing"
    },
    {
        "title": "2)",
        "body": "Subjects are given study medication after an overnight fast and 2 hours before their first meal."
    },
    {
        "title": "3)",
        "body": "Part 1 includes 4 dose cohorts:  cohorts 1 and 2 consist of 4 subjects each, whereas Cohorts 3 and 4 will consist of 8 subjects each."
    },
    {
        "title": "4)",
        "body": "Subjects are randomized at a 3 \\(active) to 1 \\(placebo) ratio."
    },
    {
        "title": "5)",
        "body": "Each subject receives a single dose of either 0.1 mg/kg \\(Cohort 1), 0.5 mg/kg \\(Cohort 2), 3 mg/kg \\(Cohort"
    },
    {
        "title": "3)",
        "body": "or 10 mg/kg \\(Cohort"
    },
    {
        "title": "4)",
        "body": "of tildrakizumab IV administered over 1 hour; a minimum of 48 hours will elapse between drug administration to subjects."
    },
    {
        "title": "6)",
        "body": "After an 8-week safety observation period, each subject in Part 1 \\(Cohorts 1 through"
    },
    {
        "title": "4)",
        "body": "receives an additional two doses of tildrakizumab IV at 0.1, 0.5, 3, and 10 mg/kg, respectively, 4 weeks apart."
    },
    {
        "title": "7)",
        "body": "On Day 2, safety assessments are performed and PK samples obtained."
    },
    {
        "title": "8)",
        "body": "Subjects receive Dose 2 on Day 56"
    },
    {
        "title": "9)",
        "body": "Subjects receive Dose 3 on Day 84"
    },
    {
        "title": "10)",
        "body": [
            "Subjects have a closeout visit within 14 days of the last safety and PK assessment.\r\n\n\n\r\n\n\n\r\n\n\nPart 2",
            {
                "title": "1.",
                "body": "Up to 40 subjects with psoriasis are enrolled in Part 2"
            },
            {
                "title": "2.",
                "body": "Subjects are put into 2 dose cohorts \\(Cohorts 5 and 6)."
            },
            {
                "title": "3.",
                "body": "Subjects in Cohort 5 receive 3 doses of 3 mg/kg tildrakizumab IV given at Week 0, 4, and"
            },
            {
                "title": "8.",
                "body": ""
            },
            {
                "title": "4.",
                "body": "Subjects in Cohort 6 receive 3 doses of 10 mg/kg tildrakizumab IV given at Week 0, 4, and"
            },
            {
                "title": "8.",
                "body": ""
            },
            {
                "title": "5.",
                "body": "Subjects are randomized in a 3:1 ratio of active to placebo."
            },
            {
                "title": "6.",
                "body": "Serum pharmacokinetic samples are obtained predose and at the intervals specified in the attached full protocol"
            },
            {
                "title": "7.",
                "body": "Subjects receive Dose 2 and 3 of tildrakizumab during their visits on Days 28 and"
            },
            {
                "title": "56.",
                "body": ""
            },
            {
                "title": "8.",
                "body": "Subjects have a closeout visit within 14 days of the last PK assessment."
            },
            {
                "title": "9.",
                "body": "A closeout visit will be scheduled within 14 days of the last PK assessment. \r\n  \r\n\n\nSkin biopsy, pharmacokinetic, and safety details are provided in the attached full protocol"
            }
        ]
    }
]